Rick Doblin
Showing 1–2 of 2 transcripts.
- Lex Fridman2h 36m
Rick Doblin: Psychedelics | Lex Fridman Podcast #202
Led by Rick Doblin, the Multidisciplinary Association for Psychedelic Studies (MAPS) has achieved Phase 3 trial results showing MDMA-assisted therapy is significantly more effective than placebo and existing antidepressants for treating severe PTSD. The organization's unique non-profit structure and regulatory strategy leverage a 1984 data exclusivity bill to fund the development of these drugs while avoiding patent monopolies, positioning MAPS to potentially approve MDMA for clinical use in late 2023. This initiative aims to fundamentally transform mental healthcare by shifting the global paradigm from prohibition to therapeutic integration, with projected licensed legalization for supervised personal use by 2035.
- The Economist7 min
How MDMA is being used to treat PTSD
With standard treatments effective in only 20% of cases, researchers led by Rick Doblin are pursuing FDA approval for MDMA-assisted therapy after trials showed over 60% of participants no longer met PTSD criteria. The non-profit-funded study utilizes a regimen of three drug sessions paired with psychotherapy to allow veterans like John Lubecki to process trauma without fear, a potential breakthrough for the 8 million Americans suffering from the disorder. Because the drug cannot be patented, this initiative by a small organization aims to transform the illicit substance into a regulated medicine that addresses a public health crisis costing the Department of Veterans Affairs $400 million annually.